Veradermics, Incorporated
MANE
$103.90
-$4.23-3.91%
NYSE
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 371.99% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 285.38% | ||||
| Operating Income | -285.38% | ||||
| Income Before Tax | -285.99% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -285.99% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -285.99% | ||||
| EBIT | -285.38% | ||||
| EBITDA | -- | ||||
| EPS Basic | -328.18% | ||||
| Normalized Basic EPS | -279.38% | ||||
| EPS Diluted | -328.18% | ||||
| Normalized Diluted EPS | -279.38% | ||||
| Average Basic Shares Outstanding | 1.75% | ||||
| Average Diluted Shares Outstanding | 1.75% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||